Nihon Medi-physics Company, Limited

Susumu Kondo

Makoto Azuma

Shigemi Seri

Kumiko Iwai

Yuji Hashiguchi

Nobuo Ueda

Masaaki Hazue

Miki Kurami

Sakae Okano

There is disclosed an imaging agent for diagnosis comprising a compound composed of a polynuclear type compound of the formula I or II: ##STR1## wherein each X is a hydrogen atom or a bifunctional ligand, at least one of them are bifunctional ligand and m or n is an integer of 1 to 6, and at least one metal ion being coordinated with at least one bifunctional ligand moiety, said metal ion being selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.

Low molecular weight polysaccharide complexes for radiation diagnosis

There is disclosed an imaging agent for diagnosis comprising a compound composed of a polynuclear type compound of the formula I or II: ##STR1## wherein each X is a hydrogen atom or a bifunctional ligand, at least one of them are bifunctional ligand and m or n is an integer or 1 to 6, and at least one metal ion being coordinated with at least one bifunctional ligand moiety, said metal ion being selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.

Low molecular weight polysaccharide complexes for X-ray imaging

Low molecular weight polysaccharide complexes for nuclear magnetic

There is disclosed a nuclear magnetic resonance imaging agent comprising a complex compound composed of (a) a dialdehyde-saccharide having a molecular weight of from 500 to 10,000, at least one of the constituent monosaccharides of which is oxidation-cleaved, (b) at least one complexing agent which is chemically coupled to an aldehyde group of the dialdehyde-saccharide and (c) a paramagnetic metal ion which is chemically coupled to the complexing agent.

Nuclear magnetic resonance imaging agent comprising a di-aldehyde complex

A compound of the formula II: ##STR1## wherein n is an integer of 2 to 10,

Diethylenetriamine pentaacetic acid derivatives

A process for preparing a radiopharmaceutical composition comprising a technetium 99m chelate complex, comprises the steps of:

Process for preparing a radiopharmaceutical composition

A compound of the formula II: ##STR1## wherein n is an integer of 2 to 10, A' is a bivalent linking group formed by reacting both the reactive groups of a cross linking reagent, and

A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen, C.sub.1 -C.sub.3 alkyl or phenyl. The agent is characteristic in having a high stability even after being administered into a human body and showing the substantially the same behavior as the physiologically active substance itself in a human body.

Growing community of inventors

Ichihara, Japan

Susumu Kondo